The application relates to a protein dimer formed by a first and a second fusion protein, wherein the first fusion protein comprises a cystine knot domain (CK) fused to a first pharmaceutically active protein and the second fusion protein comprises a CK domain fused to a second pharmaceutically active protein, wherein the two fusion proteins are covalently linked by their CK domains. The application further relates to the individual fusion proteins, to the polynucleotide encoding the fusion proteins, the vector comprising the polynucleotide and the host cell comprising the vector.
The invention relates to a high purity Coagulation Factor Xa (FXa or activated Coagulation Factor X) preparation and an activation and purification process to obtain said FXa of high purity and high degree of activation without addition of proteinaceous activators during manufacturing.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
EDP software for the prediction of chemical processes, preferably based on analytical data based on a mathematical forecasting model, in particular for the prediction of diffusion rates between materials of the same and different states of matter, for example for the prediction of extractables and leachables [E&Ls] in pharmaceutical and medical production processes Chemical/pharmaceutical testing relating to the release of harmful substances in the chemical/pharmaceutical industry, in particular relating to extractables and leachables in the manufacture of pharmaceutical products or medicines; Preparation of application-related studies into extractables and leachables, toxicological risk assessment of extractables and leachables, studies in the pharmaceutical sector relating to extractables and leachables; Development of methods and validation of methods for extractables and leachables
4.
BIODEGRADABLE, NON-POROUS MEDICAL DEVICE AND METHODS FOR MAKING AND USING THE SAME
The present invention relates to biodegradable, non-porous medical devices and particular to such devices comprising a sheet-like structural layer and a multi-layered water-activatable adhesive component. The invention further relates to methods of making and using the biodegradable, non-porous medical devices. Embodiments of the invention have been particularly developed for making flexible yet burst-resistant biodegradable, non-porous medical devices, where the devices adhesive component renders them particularly useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.
Mold for applying a liquid onto a plasma-based or cryoprecipitate-based film comprising at least one frame (1) configured for carrying said plasma-based or cryoprecipitate-based film, at least one base plate (2) and at least one mold body (3) with at least one passage (10), wherein said frame (1) is arranged between said base plate (2) and said mold body (3) such that said liquid can be applied, preferably poured or sprayed, onto said plasma-based or cryoprecipitate-based film through said passage (10). Further, a method for coating a plasma-based or cryoprecipitate-based film is described.
B05B 13/02 - Means for supporting workArrangement or mounting of spray headsAdaptation or arrangement of means for feeding work
B05B 12/20 - Masking elements, i.e. elements defining uncoated areas on an object to be coated
B05C 3/18 - Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material only one side of the work coming into contact with the liquid or other fluent material
B05C 13/02 - Means for manipulating or holding work, e.g. for separate articles for particular articles
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
EDP software for the prediction of chemical processes, preferably based on analytical data based on a mathematical forecasting model, in particular for the prediction of diffusion rates between materials of the same and different states of matter, for example for the prediction of extractables and leachables [E&Ls] in pharmaceutical and medical production processes. Chemical/pharmaceutical testing relating to the release of harmful substances in the chemical/pharmaceutical industry, in particular relating to extractables and leachables in the manufacture of pharmaceutical products or medicines; Preparation of application-related studies into extractables and leachables, toxicological risk assessment of extractables and leachables, studies in the pharmaceutical sector relating to extractables and leachables; Development of methods and validation of methods for extractables and leachables.
The present invention relates to a stable C1-esterase-inhibitor (C1-Inh) preparation, which is liquid or lyophilised, characterised by a histidine content of 5-400 mM but does not contain citrate or phosphate. It further relates to a kit including the C1-Inh preparation.
The invention relates to a fusion protein comprising: a Factor VIII (FVIII) heavy chain; an FVIII light chain; a fragment of von Willebrand Factor (VWF); and at least two copies of an extension peptide (EP); wherein the EP has at least 90 % amino acid sequence identity to SEQ ID NO: 1 and contains a cluster of O-glycosylation sites, wherein the cluster contains at least two O-glycosylated amino acids. The complex shows improved pharmacokinetic properties in comparison to FVIII. The invention further relates to a polynucleotide encoding the fusion protein as well as a vector and host cell comprising the polynucleotide.
The present invention relates to human albumin solutions and in particular to methods and uses of preparing them. The invention further relates to human albumin solutions, which have an increased mercaptalbumin content and/or an increased transport capacity for reactive oxygen species, reactive nitrogen species as well as endogenous and exogenous ligands. Embodiments of the invention have been particularly developed for use in the treatment of disease and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes and blood components, especially blood plasma Blood for medical purposes, blood components, namely, blood plasma, platelet-rich blood plasma, stem cells for medical use, bone marrow concentrate and platelets for medical use Hosting software platforms and websites on the internet for others, in the field of blood-products and information relating to blood-products and blood-donation Blood bank services, blood donation being blood bank services; providing health information relating to blood-products and blood-donation
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes and blood components, especially blood plasma Blood for medical purposes, blood components, namely, blood plasma, platelet-rich blood plasma, stem cells for medical use, bone marrow concentrate and platelets for medical use Hosting software platforms and websites on the internet for others, in the field of blood-products and information relating to blood-products and blood-donation Blood bank services, blood donation being blood bank services; providing health information relating to blood-products and blood-donation
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes and blood components, especially blood plasma Blood for medical purposes, blood components, namely, blood plasma, platelet-rich blood plasma, stem cells for medical use, bone marrow concentrate and platelets for medical use Hosting software platforms and websites on the internet for others, in the field of blood-products and information relating to blood-products and blood-donation Blood bank services, blood donation being blood bank services; providing health information relating to blood-products and blood-donation
The present invention relates to a method of modifying at least one gene in a cell via CRISPR/Cas, wherein the at least one gene has at least three alleles. The present invention further relates to cells obtainable by the method of the invention. Additionally, the present invention provides a method of producing a protein in a cell obtainable by the method of modifying at least one gene of the invention. Moreover, the invention relates to proteins obtainable by the method of producing a protein and use thereof, for example in therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, proteins, derived from solutions containing blood or blood plasma, including medicines containing antithrombin and albumin for infusions.
The present invention relates to a method of modifying at least one gene in a cell via CRISPR/Cas, wherein the at least one gene has at least three alleles. The present invention further relates to cells obtainable by the method of the invention. Additionally, the present invention provides a method of producing a protein in a cell obtainable by the method of modifying at least one gene of the invention. Moreover, the invention relates to proteins obtainable by the method of producing a protein and use thereof, for example in therapy.
The present invention relates to biodegradable, non-porous medical devices and particular to such devices comprising a sheet-like structural layer and a multi- layered water-activatable adhesive component. The invention further relates to methods of making and using the biodegradable, non-porous medical devices. Embodiments of the invention have been particularly developed for making flexible yet burst-resistant biodegradable, non-porous medical devices, where the devices adhesive component renders them particularly useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.
A61L 15/40 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof
A61L 31/00 - Materials for other surgical articles
Mold for applying a liquid onto a plasma-based or cryoprecipitate-based film comprising at least one frame (1) configured for carrying said plasma-based or cryoprecipitate-based film, at least one base plate (2) and at least one mold body (3) with at least one passage (10), wherein said frame (1) is arranged between said base plate (2) and said mold body (3) such that said liquid can be applied, preferably poured or sprayed, onto said plasma-based or cryoprecipitate-based film through said passage (10). Further, a method for coating a plasma-based or cryoprecipitate-based film is described.
B05C 3/18 - Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material only one side of the work coming into contact with the liquid or other fluent material
The invention relates to a pharmaceutical composition comprising an isolated Factor VIII protein and/or an isolated VWF protein in a stabilizing buffer composition, wherein said pharmaceutical composition is free of albumin and said stabilizing buffer 5 composition comprises cryoprotectants and bulking agents in a weight ratio of more than 0.65:1. The invention relates further relates to the use of a stabilizing buffer formulating an FVIII protein and/or a VWF protein to the use of a VWF protein for stabilizing a FVIII protein in vitro.
The present invention relates to a liquid composition comprising polyclonal immunoglobulins, at least one viscosity modulating amino acid, selected from arginine and histidine, and at least one stabilising amino acid, selected from glycine and proline, wherein more than 90% of the polyclonal immunoglobulins are in the form of monomers or dimers and less than 5% in the form of polymers, and wherein the immunoglobulin concentration in the composition is above 160 g/L and the pH is in the range from 5.2 to 5.9. The invention further relates to a liquid composition for use in medical treatment, to amino acids for formulating a highly concentrated polyclonal immunoglobulins as well as a method of formulating.
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes, blood components, especially blood plasma, and also relating to hosting product platforms and service/communication platforms on the internet, especially relating to blood-products and information relating to blood-products and blood-donation Hosting product platforms and service/communication platforms being software and websites on the internet for others, especially relating to blood-products and information relating to blood-products and blood-donation, as well as patient support information and patient support programs Blood bank services, blood donation being blood bank services; providing health information relating to blood-products and blood-donation; providing patient support information being health information Patient support programs being personal support services for families of patients with life threatening disorders, namely, companionship, help with medical forms, emotional counseling and emotional support
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes, blood components, especially blood plasma, and also relating to hosting product platforms and service/communication platforms on the internet, especially relating to blood-products and information relating to blood-products and blood-donation Hosting product platforms and service/communication platforms being software and websites on the internet for others, especially relating to blood-products and information relating to blood-products and blood-donation, as well as patient support information and patient support programs Blood bank services, blood donation being blood bank services; providing health information relating to blood products and blood donation; providing patient support information being heath information Patient support programs being personal support services for families of patients with life threatening disorders, namely, companionship, help with medical forms, emotional counseling and emotional support
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Blood for medical purposes, blood components, namely, blood plasma, platelet-rich blood plasma, stem cells for medical use, bone marrow concentrate and platelets for medical use Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes, blood components, especially blood plasma, and also relating to hosting product platforms and service/communication platforms on the internet, especially relating to blood-products and information relating to blood-products and blood-donation Hosting product platforms and service/communication platforms being software and websites on the internet for others, especially relating to blood-products and information relating to blood-products and blood-donation Blood bank services, blood donation being blood bank services; providing health information relating to blood products and blood donation
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Blood for medical purposes, blood components, namely, blood plasma, platelet-rich blood plasma, stem cells for medical use, bone marrow concentrate and platelets for medical use Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes, blood components, especially blood plasma, and also relating to hosting product platforms and service/communication platforms on the internet, especially relating to blood-products and information relating to blood-products and blood-donation Hosting product platforms and service/communication platforms being software and websites on the internet for others, especially relating to blood-products and information relating to blood-products and blood-donation Blood bank services, blood donation being blood bank services; providing health information relating to blood-products and blood-donation
40.
STORAGE STABLE FILMS COMPRISING FIBRIN AND/OR FIBRINOGEN
Described herein are dried films comprising fibrin and/or fibrinogen, and methods of using same. In certain aspects, the dried films are storage stable at room temperature. In certain aspects, the dried films described herein are effective for preventing or treating a wound in a subject in need thereof.
Advertising and business services, namely, business consulting, business administration, business operational advisory services, business marketing services, business information services, business management consulting services, business administrative services for medical and pharmaceutical referrals
42.
FX activation process and its use in the preparation of a FXa composition
The invention relates to a high purity Coagulation Factor Xa (FXa or activated Coagulation Factor X) preparation and an activation and purification process to obtain said FXa of high purity and high degree of activation without addition of proteinaceous activators during manufacturing.
The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.
The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.
A61L 15/40 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof
A61L 31/00 - Materials for other surgical articles
47.
Plasma-based films and methods for making and using the same
The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.
A61L 15/40 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof
A61L 31/00 - Materials for other surgical articles
The present invention relates to a stable C1-esterase-inhibitor (C1-Inh) preparation, which is liquid or lyophilised, characterised by a histidine content of 5-400 mM but does not contain citrate or phosphate. It further relates to a kit including the C1-Inh preparation.
The invention relates to a high purity Coagulation Factor Xa (FXa or activated Coagulation Factor X) preparation and an activation and purification process to obtain said FXa of high purity and high degree of activation without addition of proteinaceous activators during manufacturing.
The invention provides a method for separating a Factor VIII (FVIII) protein from a first composition comprising the FVIII protein, which contains at least the light chain of FVIII, and a von-Willebrand-Factor (vWF) protein which comprises at least the FVIII binding domain of vWF, wherein the FVIII protein can form a complex with the vWF protein, the method comprising the steps: contacting the first composition with an affinity resin comprising a ligand and a matrix, wherein the ligand has an affinity to the light chain of FVIII, and separating the affinity resin from the mixture to obtain a modified first composition and a second composition, wherein the second composition contains the affinity resin, and a complex of the FVIII protein and the vWF protein.
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.
The present invention relates to a method of modifying at least one gene in a cell via CRISPR/Cas, wherein the at least one gene has at least three alleles. The present invention further relates to cells obtainable by the method of the invention. Additionally, the present invention provides a method of producing a protein in a cell obtainable by the method of modifying at least one gene of the invention. Moreover, the invention relates to proteins obtainable by the method of producing a protein and use thereof, for example in therapy.
The invention relates to a fusion protein comprising a main protein and one or more extension peptides, wherein the amino acid sequence of the main protein is identical or similar to the amino acid sequence of a mammalian protein or a fragment thereof, and said extension peptide comprises a cluster of O-glycosylated amino acids. The extension peptide is identical to a non-repeated sequence of the mammalian protein and/or identical or similar to SEQ ID NO: 1. The main protein is preferably VWF. The fusion protein has an increased half life as compared to the main protein and may be used to increase the half-life of a binding partner, e.g. FVIII. The invention further relates to the complex formed by the fusion protein, a polynucleotide encoding the fusion protein as well as a vector and host cell comprising the polynucleotide.
The present invention relates to a liquid composition comprising polyclonal immunoglobulins, at least one viscosity modulating amino acid, selected from arginine and histidine, and at least one stabilising amino acid, selected from glycine and proline, wherein more than 90% of the polyclonal immunoglobulins are in the form of monomers or dimers and less than 5% in the form of polymers, and wherein the immunoglobulin concentration in the composition is above 160 g/L and the pH is in the range from 5.2 to 5.9. The invention further relates to a liquid composition for use in medical treatment, to amino acids for formulating a highly concentrated polyclonal immunoglobulins as well as a method of formulating.
A process for purifying fibrinogen from a fibrinogen containing source by precipitation of fibrinogen by a precipitating agent from a fibrinogen containing solution in the presence of one or more chelating agent(s) and removal of the supernatant from the fibrinogen paste, characterised in that fibrinogen is extracted from the paste forming a liquid fraction containing fibrinogen, and an undissolved residue, which is separated from the liquid.
The present invention relates to a stable C1-esterase-inhibitor (C1-Inh) preparation, which is liquid or lyophilised, characterised by a histidine content of 5-400 mM but does not contain citrate or phosphate. It further relates to a kit including the C1-Inh preparation.
The present invention relates to a method for the production of a recombinant target protein, in particular to a method comprising culturing a human host cell in a fortified cell culture medium. Embodiments of the invention were particularly developed for increasing the cell-specific productivity of host cells transfected with a nucleic acid sequence encoding human blood proteins such as coagulation Factor VIII (FVIII) and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.
A composition comprising a complex of Factor VIII and one or more Von Willebrand Factor peptides, wherein the Von Willebrand Factor peptides comprise at least the amino acids 764 to 1035 and 1691 to 1905 of SEQ ID No. 1 but not amino acids 2255 to 2645 of SEQ ID No. 1.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical products, namely blood coagulation factors, particularly recombinant factors VIII. Computer-software, especially on the basis of a mathematical model for prediction of the FVIII concentration in human plasma, especially after infusion of a dose of a blood coagulation factor, particularly based on a bayesian model to predict pharmaco kinetics. Medical and pharmaceutical information retrieval services; the aforementioned services both via hardcopy and/or internet. Providing information relating to medical and pharmaceutical services; the aforementioned services both via hardcopy and/or internet.
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Computer-software, especially on the basis of a mathematical model to predict pharmaco kinetics after infusion of a dose of medicines containing immunoglobulin. Medical and pharmaceutical information retrieval services; the aforementioned services both via hardcopy and/or internet. Providing information relating to medical and pharmaceutical services; the aforementioned services both via hardcopy and/or internet.
61.
HIGH CONCENTRATION IMMUNOGLOBULIN COMPOSITION FOR PHARMACEUTICAL APPLICATION
The present invention relates to a liquid composition comprising polyclonal immunoglobulins, at least one viscosity modulating amino acid, selected from arginine and histidine, and at least one stabilising amino acid, selected from glycine and proline, wherein more than 90% of the polyclonal immunoglobulins are in the form of monomers or dimers and less than 5% in the form of polymers, and wherein the immunoglobulin concentration in the composition is above 160 g/L and the pH is in the range from 5.2 to 5.9. The invention further relates to a liquid composition for use in medical treatment, to amino acids for formulating a highly concentrated polyclonal immunoglobulins as well as a method of formulating.
The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.
The invention relates to a fusion protein comprising a main protein and one or more extension peptides, wherein the amino acid sequence of the main protein is identical or similar to the amino acid sequence of a mammalian protein or a fragment thereof, and said extension peptide comprises a cluster of O-glycosylated amino acids. The extension peptide is identical to a non-repeated sequence of the mammalian protein and/or identical or similar to SEQ ID NO: 1. The main protein is preferably VWF. The fusion protein has an increased half life as compared to the main protein and may be used to increase the half-life of a binding partner, e.g. FVIII. The invention further relates to the complex formed by the fusion protein, a polynucleotide encoding the fusion protein as well as a vector and host cell comprising the polynucleotide.
The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, particularly blood plasma
preparations, plasma derivatives, coagulation factors,
growth factors, proteins derived from plasma. Treatment of materials, namely treatment of blood or blood
plasma in pharmaceutical preparations, particularly of blood
plasma preparations, plasma derivatives, coagulation
factors, growth factors, proteins derived from plasma. Medical services, particularly the medical services of a
blood donation center.
The invention provides a method for separating a Factor VIII (FVIII) protein from a first composition comprising the FVIII protein, which contains at least the light chain of FVIII, and a von-Willebrand-Factor (vWF) protein which comprises at least the FVIII binding domain of vWF, wherein the FVIII protein can form a complex with the vWF protein, the method comprising the steps: contacting the first composition with an affinity resin comprising a ligand and a matrix, wherein the ligand has an affinity to the light chain of FVIII, and separating the affinity resin from the mixture to obtain a modified first composition and a second composition, wherein the second composition contains the affinity resin, and a complex of the FVIII protein and the vWF protein.
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
40 - Treatment of materials; recycling, air and water treatment,
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Treatment of materials, namely, treatment of blood or blood plasma in pharmaceutical preparations, particularly of blood plasma preparations, plasma derivatives, coagulation factors, growth factors, proteins derived from plasma Pharmaceutical preparations, particularly blood plasma preparations, plasma derivatives, coagulation factors, growth factors, proteins derived from plasma Medical services, particularly the medical services of a blood donation center
The present invention provides a method for increasing the yield of a protein produced by cultivating eukaryotic cells and adding an ionic substance to the culture medium prior to harvest of the protein. Suitable ionic substances are the salts of the Hofmeister series, amino acids and peptone.
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, particularly blood plasma preparations, plasma derivatives, coagulation factors, growth factors, proteins derived from plasma. Treatment of materials, namely treatment of blood or blood plasma in pharmaceutical preparations, particularly of blood plasma preparations, plasma derivatives, coagulation factors, growth factors, proteins derived from plasma. Medical services, particularly the medical services of a blood donation center.
80.
Process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII/AG
A process for manufacturing of a Factor VIII product having a ratio of FVIII:C/FVIII:Ag of at least 0.7 in the Factor VIII product by using chromatography wherein at least one chromatographic step is performed by means of employing; An affinity chromatography resin having an affinity for specifically binding of Factor VIII which is effected by an affinity ligand which is immobilised on the affinity chromatography resin, said affinity ligand is a 13 kD yeast derived Fab antibody fragment directed to the Factor VIII molecule. An anionic chromatography resin. A size exclusion resin. A Factor VIII product obtainable according to the process with a monomer content of >98% for treatment of haemophilia and avoiding formation of inhibitors.
The present invention relates to a method or process for the manufacture of a virus and prion save native fibrinogen concentrate of high purity and low amounts of fibrinopeptide A and fibronectin.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Training people with blood clotting disorders and their
relatives for the treatment of the illness in private life,
in particular for self-injection of blood coagulation
factors or for administration of drugs for the treatment of
blood coagulation disorders. Medical advice to patients with blood clotting disorders.
(1) Sterile, single use, disposable, needleless medical device for the reconstitution and transfer of drugs for intravenous application for the treatment of acute or traumatic bleeding episodes in patients with fibrinogen deficiency
Medical apparatus and instruments for reconstituting lyophilized fibrinogen powder; medical devices for transferring water to lyophilized fibrinogen powder to reconstitute the fibrinogen for preparation of fibrinogen solutions for injections and infusions
97.
PREPARATION COMPRISING FACTOR VIII AND VON WILLEBRAND FACTOR PEPTIDES
A composition comprising a complex of Factor VIII and one or more Von Willebrand Factor peptides, wherein the Von Willebrand Factor peptides comprise at least the amino acids 764 to 1035 and 1691 to 1905 of SEQ ID No. 1 but not amino acids 2255 to 2645 of SEQ ID No. 1.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A process for manufacturing of a Factor VIII product having a ratio of FVIII :C/FVIII :Ag of at least 0.7 in the Factor VIII product by using chromatography wherein at least one chromatographic step is performed by means of employing; • An affinity chromatography resin having an affinity for specifically binding of Factor VIII which is effected by an affinity ligand which is immobilised on the affinity chromatography resin, said affinity ligand is a 13 kD yeast derived Fab antibody fragment directed to the Factor VIII molecule. • An anionic chromatography resin. • A size exclusion resin. A Factor VIII product obtainable according to the process with a monomer content of >98 % for treatment of haemophilia and avoiding formation of inhibitors.
